On Monday, Senomyx Inc. (NASDAQ:SNMX)’s shares inclined 12.24% to $6.97.
Senomyx, Inc. (SNMX), a leading company using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients for the food, beverage, and ingredient supply industries, stated financial results for the second quarter 2015.
Q2 2015 Financial Results:
At June 30, 2015, Senomyx held $24.8 million in cash, cash equivalents and investments accessible-for-sale.
Development revenues were $4.6 million in the second quarter of 2015 contrast to $5.9 million in the second quarter of 2014. Development revenues were $8.9 million for the six months ended June 30, 2015 contrast to $12.7 million for the same period in 2014. This decrease was primarily due to a $2.8 million decrease in development revenue resulting from an extension of the revenue recognition period for the PepsiCo Sweet Taste Program partnershiplicense fee, in accordance with PepsiCo’s election in May 2014 to extend the research funding period for an additional two years to August 2016. There was no impact on cash flow because the $30 million of license fee payments were received in 2010.
Senomyx, Inc. discovers, develops, and commercializes flavor ingredients for the packaged food, beverage, and ingredient supply industries using proprietary taste receptor-based assays and screening technologies. The company focuses on the discovery, development, and/or commercialization of flavor ingredients through five programs focused on sweet, savory, bitter, cooling, and salt taste areas.
Towers Watson & Co (NASDAQ:TW)’s shares gained 1.51% to $128.69.
Global professional services company Towers Watson (TW) has introduced Towers Watson DataValidator, a data validation and transformation software solution that assists insurers use their data more efficiently across financial modeling analytics, pricing applications and risk administration.
DataValidator assists insurers meet evolving regulatory data quality requirements against recently’s increasingly challenging timetables. The solution provides a quick and comprehensive data quality assessment while providing thorough audit trails necessary for mandatory governance and audit readiness.
DataValidator is developed, maintained and supported by Towers Watson. It operates with Towers Watson risk software products and third-party software solutions.
Towers Watson & Co., a professional services company, provides human capital and financial consulting services worldwide. The company’s Benefits segment provides benefits consulting and administration services, such as retirement solutions, which provides actuarial and consulting services for large defined benefit and defined contribution plans, counting consulting on plan design, funding, and risk administration strategies; health and group benefits services, such as plan administration consulting across the health and group benefit programs, counting health, dental, disability, life, and other coverage.
At the end of Monday s trade, Halozyme Therapeutics, Inc. (NASDAQ:HALO)‘s shares dipped -1.33% to $23.03.
Halozyme Therapeutics, Inc. (HALO) will webcast its Quarterly Update Conference Call for the second quarter 2015 on Monday, August 10, 2015 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the second quarter 2015.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX), ended its Monday’s trading session with -3.01% loss, and closed at $64.42.
Pacira Pharmaceuticals, Inc. (PCRX) declared that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is planned to present an overview of the company at the following investor conferences in August:
Wedbush 2015 Life Sciences Administration Access Conference at 8:00 a.m. ET in New York on Tuesday, August 11, 2015.
Canaccord Genuity’s 35th Annual Growth Conference at 9:00 a.m. ET in Boston on Wednesday, August 12, 2015.
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
